Vistagen Therapeutics, Inc.
VTGN Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.17
KIRA · Stoqly’s AI analyst, in plain words
- Vistagen Therapeutics, Inc. had $1.3M of revenue in fiscal 2026, up 161.1% on the year before. Over five years, revenue changed +3.1% a year on average.
- Its operating margin was −5,683.7%, up 5,833.4 pts: of every 100 in sales, about −5,684 is left after running the business.
- Vistagen Therapeutics, Inc. lost $69.7M in fiscal 2026.
Market cap
$7.5M
P/E
—
Revenue
$1.3M
Net income
−$69.7M
Free cash flow
—
Operating margin
−5,683.7%
Vistagen Therapeutics, Inc. in 30 seconds · fiscal 2026
Are sales growing?
+161.1%
Yes. Sales grew 161.1% last year.
Does it make a profit?
−5,491.3%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Vistagen Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · Jun 15, 2026
- Legal name
- Vistagen Therapeutics, Inc.
- CIK
- 0001411685
Vistagen Therapeutics, Inc. · VTGN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.1M | −$0.2M | $1.1M | $0.5M | $1.3M |
| Revenue growth | 1.8% | −120.5% | — | −54.3% | 161.1% |
| Net interest income | $0.0M | $0.0M | — | — | — |
| Operating margin | −4,308.3% | 26,109.3% | −3,103.5% | −11,517.1% | −5,683.7% |
| Net income | −$47.8M | −$59.2M | −$29.4M | −$51.4M | −$69.7M |
| Net margin | −4,306.8% | 26,100.4% | −2,759.6% | −10,579.8% | −5,491.3% |
| Diluted EPS | — | −$8.51 | −$1.52 | −$1.67 | −$1.83 |
| Cash | |||||
| Cash from operations | −$45.3M | −$49.7M | −$25.8M | −$42.1M | −$66.4M |
| Capital expenditure | $0.2M | $0.5M | $0.0M | — | — |
| Free cash flow | −$45.5M | −$50.2M | −$25.8M | — | — |
| FCF margin | −4,098.9% | 22,133.9% | −2,426.0% | — | — |
| Share count change | — | — | 178.1% | 59.5% | 23.3% |
| Debt and strength | |||||
| Cash and short-term investments | $68.1M | $16.6M | $119M | $80.5M | $45.4M |
| Shareholders' equity | $64.7M | $12.1M | $114M | $70.4M | $35.5M |
| Current ratio | 12.3x | 3.8x | 23.6x | 6.5x | 3.7x |
| Returns and quality | |||||
| Return on equity | −61.0% | −154.3% | −46.5% | −55.7% | −131.6% |
| Return on tangible equity | −75.3% | −490.5% | −25.7% | −73.0% | −196.2% |
| Piotroski F-score | — | — | 4 | 1 | 2 |
| Altman Z'' | −3.4 | −64.0 | 7.8 | −9.5 | −34.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vistagen Therapeutics, Inc. · VTGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.17 a share, the company is worth $7.5M.
Source: SEC EDGAR XBRL filings (CIK 0001411685). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.